Centrum Broking: Sanofi India Posts Steady Quarter Aided By Lower Spend During Pandemic 
Blister packs containing Priadel tablets, produced by Sanofi, sit on a pharmacy counter in this arranged photograph in London, U.K. (Photographer: Chris Ratcliffe/Bloomberg)

Centrum Broking: Sanofi India Posts Steady Quarter Aided By Lower Spend During Pandemic 

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Centrum Broking Report

Sanofi India Ltd. delivered quarterly earnings ahead of our estimates. It reported decline in revenue by 5% YoY, but the results are not exactly comparable as Ankleshwar hive-off to Zentiva was completed on May 29, 2020.

The continuing operations have reported nearly 1% YoY growth. Gross margins were at 55.5% versus 54.4% YoY versus 56.6% QoQ. Staff cost was up 8% YoY while other expenses declined 31%YoY.

The Ebitda at Rs 1.77 billion increased 12% YoY while flat QoQ. Ebitda margins at 24.9% improved 380 basis points YoY. With in-line other income, depreciation and effective tax rate, the profit after tax for the quarter stood at Rs 1.36 billion, up 30% YoY and flat QoQ (adjusted impairment).

Click on the attachment to read the full report:

Centrum Sanofi India Q2CY20 Results Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.